Cargando…
What to Test in Parkinson Disease Prevention Trials?: Repurposed, Low-Risk, and Gene-Targeted Drugs
Despite the sound epidemiologic and basic science rationales underpinning numerous “disease modification” trials in manifest Parkinson disease (PD), none has convincingly demonstrated that a treatment slows progression. Rapidly expanding knowledge of the genetic determinants and prodromal features o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519134/ https://www.ncbi.nlm.nih.gov/pubmed/35970592 http://dx.doi.org/10.1212/WNL.0000000000200238 |